Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy (scientific article published on December 2008)

A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection

Q54246961

Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines

Q54690366

Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor- Type I Receptor Kinase In vivo

Q59383502

Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity

Q71961232

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

Q80244014

Transforming growth factor-beta pathway serves as a primary tumor suppressor in CD8+ T cell tumorigenesis

Q80579661

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

Q34328457

Leukocyte recruitment at sites of tumor: dissonant orchestration

Q34330220

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

Q34556464

Transforming growth factor-beta in T-cell biology

Q34572232

Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment

Q34761564

Development of TGF-beta signalling inhibitors for cancer therapy

Q35968389

Role of transforming growth factor Beta in human cancer

Q36073421

Targeting TGFbeta signaling for cancer therapy

Q36104380

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

Q36254020

T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress

Q36317667

Inhibition of TGFbeta signaling in cancer therapy

Q36353153

Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response

Q36369397

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

Q36402716

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

Q36464443

Immune suppression in the tumor microenvironment

Q36478177

Tumor-driven evolution of immunosuppressive networks during malignant progression

Q36494855

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms

Q36568027

Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers

Q36801053

TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells

Q36924688

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17

Q36981811

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Q36983438

SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model

Q40023848

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses

Q40099218

TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.

Q40138388

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Q40266751

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

Q40351779

Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung.

Q40372805

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

Q40400501

Establishment of a murine model of malignant mesothelioma

Q42805719

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Q42810754

Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.

Q42949508

Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

Q43409838

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

Q45287769

Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta

Q45306492

Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity

Q45879215

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Q45885336

Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma

Q46853209

TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors

Q48434089

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer

Q50775718

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity

Q53886026

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

10247-10256

P577

publication date

2008-12-01

P1433

published in

Cancer Research

Q326097

P1476

title

Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy

P478

volume

Reverse relations

cites work (P2860)

Q36710130	A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.
Q33796126	Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
Q59329445	Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus
Q57440780	Asbestos and Lung Disease
Q39137992	Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.
Q33637647	Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells
Q38714700	Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy.
Q33651427	CCL2 blockade augments cancer immunotherapy
Q35964158	Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment
Q29994573	Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
Q28075996	Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity
Q58794926	EGFR may participate in immune evasion through regulation of B7‑H5 expression in non‑small cell lung carcinoma
Q36874759	Fowlpox‐based survivin vaccination for malignant mesothelioma therapy
Q37790599	Harnessing the immune response to treat cancer
Q35711576	Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
Q28390399	Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
Q34654430	Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
Q34618985	Kinetics of Host Cell Recruitment During Dissemination of Diffuse Malignant Peritoneal Mesothelioma
Q26866223	NKT cell networks in the regulation of tumor immunity
Q37731681	Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment
Q39026688	Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity
Q37855667	Novel Targeted Therapies and Vaccination Strategies for Mesothelioma
Q29619346	Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
Q55267052	Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.
Q28081170	Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review)
Q52629273	Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients
Q34275601	Strategies to use immune modulators in therapeutic vaccines against cancer
Q35033957	Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination
Q33581597	Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody
Q37438563	Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines
Q33936542	TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression
Q97867213	TGFβ biology in cancer progression and immunotherapy
Q38241602	TGFβ: A player on multiple fronts in the tumor microenvironment.
Q39155151	Targeting TGF-β Signaling for Therapeutic Gain
Q36462348	Targeting the TGFβ signalling pathway in disease
Q35176307	Targeting the tumor microenvironment to enhance antitumor immune responses
Q28241308	The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Q38365115	The immune suppressive function of transforming growth factor-β (TGF-β) in human diseases
Q38995979	The importance of correctly timing cancer immunotherapy
Q37454364	The polarization of immune cells in the tumour environment by TGFbeta
Q33630845	The roles of TGFβ in the tumour microenvironment
Q36098663	The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer.
Q37828885	Therapeutic vaccination against human papilloma virus induced malignancies
Q27007473	Therapy of human papillomavirus-related disease
Q58777562	Tissue-Specific Roles of NKT Cells in Tumor Immunity
Q43727484	Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA.
Q39087629	Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression
Q39079703	Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs
Q37994480	Tumor-associated neutrophils: friend or foe?
Q92502928	Tumour-associated neutrophils in patients with cancer
Q37123849	Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
Q36989720	Update on vaccine development for renal cell cancer
Q36747346	Using macrophage activation to augment immunotherapy of established tumours

P356	DOI	10.1158/0008-5472.CAN-08-1494
P932	PMC publication ID	2637471
P698	PubMed publication ID	19074893